UTRGV to break ground on Institute for Neuroscience Nov. 6

Translate to Spanish or other 102 languages!

Rendering of the Institute for Neuroscience that will be located in Harlingen, Texas.

Mega Doctor News

- Advertisement -

WHAT: Groundbreaking for UTRGV’s Institute of Neuroscience WHEN: 9 a.m. Wednesday, Nov. 6, 2019 WHERE: Haine Drive and N. Whalen Road, Harlingen, Texas

HARLINGEN, TEXAS – UTRGV will break ground on The Institute for Neuroscience, an interdisciplinary institute within the UTRGV School of Medicine, on Wednesday, Nov. 6, in Harlingen.

The world-class clinical and research site, located at Haine Drive and North Whalen Road, will house clinics and diagnostic centers for numerous neuropsychiatric and aging disorders, as well as leading the way in clinical and laboratory research for the Rio Grande Valley.

- Advertisement -

The two-story facility will serve as an incubator to train future neurologists, psychiatrists and neuroscientists. In the state-of-the-art space, clinicians and scientists will interact to develop and test new ideas for behavioral health and neurological care. 

Over time, specialties available at the institute will include cerebrovascular disease, neuromuscular disease, memory disorders, multiple sclerosis, epilepsy, other neurodegenerative diseases associated with aging and behavioral health issues across the lifespan.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.
- Advertisement -